Studies with herpes zoster vaccines in immune compromised patients

Expert Review of Vaccines

Volumn 16, Issue 12, 2017, Pages 1217-1230

  Levin, Myron J ^a   Bresnitz, Eddy ^b   Popmihajlov, Zoran ^b   Weinberg, Adriana ^a   Liaw, Kai Li ^b   Willis, English ^b   Curtis, Jeffrey R ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Herpes zoster; herpes zoster vaccine; immune compromised patient; vaccines

Indexed keywords

BIOLOGICAL PRODUCT; FINGOLIMOD; INACTIVATED VIRUS VACCINE; JANUS KINASE INHIBITOR; LIVE VACCINE; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR INHIBITOR; VARICELLA ZOSTER VACCINE;

DRUG CONTRAINDICATION; END STAGE RENAL DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; INFLAMMATORY BOWEL DISEASE; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; OFF LABEL DRUG USE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SOLID MALIGNANT NEOPLASM; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS STRAIN; IMMUNOLOGY; OBSERVATIONAL STUDY;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNOCOMPROMISED HOST; OBSERVATIONAL STUDIES AS TOPIC; PRACTICE GUIDELINES AS TOPIC; VACCINES, ATTENUATED;

EID: 85034085230     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2017.1395703     Document Type: Review

References (111)

1. Levin MJ., Zoster Vaccine. In: Plotkin S, Orenstein W, Offitt P, et al., editors. Vaccines. 7th ed. Philadelphia: Elsevier; 2017. p. 1268–1281.
2. Gershon AA, Gershon MD., Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev. 2013;26(4):728–743.
3. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341–357.
4. Weinberg A, Lazar AA, Zerbe GO, et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis. 2010;201(7):1024–1030.
5. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–1349.
6. Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325–334.
7. Forbes HJ, Thomas SL, Smeeth L, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157:30–54.
8. Schmader KE, Levin MJ, Gnann JW, Jr., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922–928.
9. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–2284.
10. Baxter F, Bartlett J, Fireman B, et al. Effectiveness of live zoster vaccine in preventing herpes zoster. Poster Abstract 1928. In: IDWeek 2015. (San Diego, 2015)
11. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825–835.
12. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. Jama. 2011;305(2):160–166.
13. Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420.
14. Marin M, Yawn BP, Hales CM, et al. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother. 2015;11(5):1157–1164.
15. Tseng HF, Harpaz R, Luo Y, et al. Declining effectiveness of herpes zoster vaccine in adults aged >/=60 years. J Infect Dis. 2016;213:1872–1875.
16. Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. (2007);56(RR-4): 1–40.
17. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2008;57(RR–5):1–30; quiz CE32-34.
18. Jura E, Chadwick EG, Josephs SH, et al. Varicella-zoster virus infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J. 1989;8(9):586–590.
19. Feldman S, Hughes WT, Daniel CB. Varicella in children with cancer: seventy-seven cases. Pediatrics. 1975;56(3):388–397.
20. Maves RC, Tripp MS, Dell TG, et al. Disseminated vaccine-strain varicella as initial presentation of the acquired immunodeficiency syndrome: a case report and review of the literature. J Clin Virol. 2014;59(1):63–66.
21. Merck & Co I. Zostavax (Zoster vaccine live) product insert. In: www.merck.com. (online, 2014) 1–12.
22. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–e100.
23. Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med. 2010;362(4):314–319.
24. Shiraki K, Matsui S, Aiba N. Susceptibility of Oka varicella vaccine strain to antiviral drugs. Vaccine. 1993;11(14):1380–1382.
25. Curtis KK, Connolly MK, Northfelt DW. Live, attenuated varicella zoster vaccination of an immunocompromised patient. J Gen Intern Med. 2008;23(5):648–649.
26. Costa E, Buxton J, Brown J, et al. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Reports, (2016).
27. Young EJ. Risk of disseminated disease in immunosuppressed patients receiving live zoster vaccine. Mayo Clin Proc. 2016;91(7):971.
28. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139(2):305–310.
29. Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis. 2006;194(2):247–255.
30. Bekker V, Westerlaken GH, Scherpbier H, et al. Varicella vaccination in HIV-1-infected children after immune reconstitution. Aids. 2006;20(18):2321–2329.
31. Armenian SH, Han JY, Dunaway TM, et al. Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1. Pediatr Infect Dis J. 2006;25(4):368–370.
32. Taweesith W, Puthanakit T, Kowitdamrong E, et al. The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2011;30(4):320–324.
33. Knorr A, Hutchison E, Finn A. Varicella vaccination for HIV-infected children. Arch Dis Child. 2008;93(9):812.
34. Son M, Shapiro ED, LaRussa P, et al. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis. 2010;201(12):1806–1810.
35. Gershon AA, Levin MJ, Weinberg A, et al. A phase I-Ii study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J. 2009;28(7):653–655.
36. Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin. 2010;6(4):318–321.
37. Benson CA, Hua L, Andersen J, et al. Zostavax is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a Phase 2, randomized, double-blind, placebo-controlled trial. (Conference on Retroviruses and Opportunistic Infections (CROI), 19th CROI, 2012 Mar5–8, Seattle, WA., 2012)
38. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414–422.
39. McNutt R. Shingles vaccine for autoimmune disease patients. Update on herpes zoster (shingles) vaccine for autoimmune disease patients. (Online, 2012) 2.
40. Singh JA, Saag KG, Bridges SL, Jr., et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology. 2016;68(1):1–26.
41. NCCN. NCCN guidelines for supportive care: survivorship. (National Comprehensive Cancer Network, Inc., Online, 2013)
42. Gov.UK/Publications. Shingles: the Green Book Chapter 28a. In: Green Book (Public Health England, 2015) 1–16.
43. (ATAGI) ATAGoI. 1.24 Zoster (herpes zoster). In: Australian Immunisation Handbook, 10th Edition. (Australian Government Department of Health, online, 2015)
44. NACI. An advisory committee statement (ACS) - National Advisory Committee on Immunization (NACI): update on the use of herpes zoster vaccine (Government of Canada, online, 2014)
45. Canada PHAo. Update on the use of herpes zoster vaccine. An Advisory Committee Statement (ACS) - National Advisory Committee on Immunization (NACI). (National Advisory Committee on Immunizations (NACI), Canadian Government, 2014)
46. Oxman MN, Schmader KE. Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations. Clin Infect Dis. 2014;59(7):920–922.
47. Lobermann M, Borso D, Hilgendorf I, et al. Immunization in the adult immunocompromised host. Autoimmun Rev. 2012;11(3):212–218.
48. Bijl M, Agmon-Levin N, Dayer JM, et al. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev. 2012;11(8):572–576.
49. Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis. 2008;197(Suppl 2):S237–S241.
50. Duchet-Niedziolka P, Launay O, Coutsinos Z, et al. Vaccination in adults with auto-immune disease and/or drug related immune deficiency: results of the GEVACCIM Delphi survey. Vaccine. 2009;27(10):1523–1529.
51. Koenig HC, Garland JM, Weissman D, et al. Vaccinating HIV patients: focus on human papillomavirus and herpes zoster vaccines. AIDS Reviews. 2013;15(2):77–86.
52. Levin MJ, Anderson JP, Seage GR, 3rd, et al. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr. 2009;50(2):182–191.
53. Blank LJ, Polydefkis MJ, Moore RD, et al. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. J Acquir Immune Defic Syndr. 2012;61(2):203–207.
54. Grabar S, Tattevin P, Selinger-Leneman H, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2015;60(8):1269–1277.
55. Weinberg A, Huang S, Song LY, et al. Immune correlates of herpes zoster in HIV-infected children and youth. J Virol. 2012;86(5):2878–2881.
56. Editors. Corrections to article Rubin, et al. CID 2014:58-e44-100. Clin Infect Dis. 2014;59(1):144–145.
57. Munshi N, Longo DL, Anderson KD. Plasma cell disorders. In: Longo D, Jameson J, Loscalzo J, et al., editors. Harrison’s principles of internal medicine. 19th ed. New York: McGraw-Hill; 2015. p. 710–719.
58. Longo D. Malignancies of lymphoid cells. In: Long D, Jameson J, Loscalzo J, et al., editors. Harrison’s principles of internal medicine. 19th ed. New York: McGraw-Hill; 2015. p. 695–710.
59. Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):240–249.
60. Habel LA, Ray GT, Silverberg MJ, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiology, Biomarkers & Prevention: a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2013;22(1):82–90.
61. Yenikomshian MA, Guignard AP, Haguinet F, et al. The epidemiology of herpes zoster and its complications in Medicare cancer patients. BMC Infect Dis. 2015;15:106.
62. Naidus E, Damon L, Schwartz BS, et al. Experience with use of Zostavax((R)) in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am J Hematol. 2012;87(1):123–125.
63. Ljungman P, Wang FZ, Nilsson C, et al. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study. Support Care in Cancer. 2003;11(11):739–741.
64. Sasadeusz J, Prince HM, Schwarer A, et al. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation. Transpl Infect Dis. 2014;16(6):1024–1031.
65. Sauerbrei A, Prager J, Hengst U, et al. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant. 1997;20(5):381–383.
66. Kussmaul SC, Horn BN, Dvorak CC, et al. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant. 2010;45(11):1602–1606.
67. Chou JF, Kernan NA, Prockop S, et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2011;17(11):1708–1713.
68. Issa NC, Marty FM, Leblebjian H, et al. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014;20(2):285–287.
69. Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant. 2000;6(1):44–49.
70. Blennow O, Fjaertoft G, Winiarski J, et al. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis–the incidence remains high. Biol Blood Marrow Transplant. 2014;20(10):1646–1649.
71. Vermont CL, Jol-van der Zijde EC, Hissink Muller P, et al. Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity. Transpl Infectious Disease: Official Journal Transplant Soc. 2014;16(2):188–194.
72. Truong Q, Veltri L, Kanate AS, et al. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients. Ann Hematol. 2014;93(4):677–682.
73. Kawamura K, Hayakawa J, Akahoshi Y, et al. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. Int J Hematol. 2015;102(2):230–237.
74. Boeckh M, Kim HW, Flowers ME, et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation–a randomized double-blind placebo-controlled study. Blood. 2006;107(5):1800–1805.
75. Van Besouw NM, Verjans GM, Zuijderwijk JM, et al. Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients. J Med Virol. 2012;84(12):2018–2025.
76. Kuo CC, Lee CT, Lee IM, et al. Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study. Am J Kidney Dis. 2012;59(3):428–433.
77. Lin SY, Liu JH, Lin CL, et al. A comparison of herpes zoster incidence across the spectrum of chronic kidney disease, dialysis and transplantation. Am J Nephrol. 2012;36(1):27–33.
78. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for herpes zoster: population based case-control study. Bmj. 2014;348:g2911.
79. CDC. Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease. In: CDC. Centers for Disease Control and Prevention. (online, 2012)
80. Tseng HF, Luo Y, Shi J, et al. Effectiveness of herpes zoster vaccine in patients 60 years and older with end-stage renal disease. Clin Infect Dis. 2016;62(4):462–467.
81. Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis & Rheumatology (Hoboken, N.J.). 2016;68(9):2328–2337.
82. Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res. 2015;67(5):731–736.
83. Shalom G, Zisman D, Bitterman H, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study. JAMA Dermatology. 2015;151(5):533–538.
84. Che H, Lukas C, Morel J, et al. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014;81(3):215–221.
85. Pappas DA, Hooper MM, Kremer JM, et al. Herpes Zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs. Arthritis Care Res. 2015;67(12):1671–1678.
86. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479–488.
87. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis & Rheumatology. 2014;66(10):2675–2684.
88. Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843–1847.
89. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. Jama. 2013;309(9):887–895.
90. Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):31–39.
91. Yun H, Xie F, Baddley JW, et al. Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol. 2017;44(7):1083–1087.
92. Wine-Lee L, Keller SC, Wilck MB, et al. From the medical board of the national psoriasis foundation: vaccination in adult patients on systemic therapy for psoriasis. J Am Acad Dermatol. 2013;69(6):1003–1013.
93. Guthridge JM, Cogman A, Merrill JT, et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013;40(11):1875–1880.
94. Sotelo J. On the viral hypothesis of multiple sclerosis: participation of varicella-zoster virus. J Neurol Sci. 2007;262(1–2):113–116.
95. Sotelo J, Ordonez G, Pineda B. Varicella-zoster virus at relapses of multiple sclerosis. J Neurol. 2007;254(4):493–500.
96. Rutschmann OT, McCrory DC, Matchar DB. Immunization and MS: a summary of published evidence and recommendations. Neurology. 2002;59(12):1837–1843.
97. Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol. 2011;258(7):1197–1206.
98. Ross R, Dawood M, Cheang M, et al. Antibody response in seropositive multiple sclerosis patients vaccinated with attenuated live varicella zoster virus. Can J Infect Dis. 1996;7(5):303–306.
99. McGraw C, Inglese M, Hannigan C, et al. An open-label observational pilot study to evaluate the safety and immunogenicity of the herpes zoster vaccine in patients with multiple sclerosis. In: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. (ECTRIMS, Lyon, France, 2012)
100. Tseng HF, Tartof S, Harpaz R, et al. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis. 2014;59(7):913–919.
101. Lindsey S, Oufnac B, Walker H, Safety of Zoster vaccination administration in rheumatic patients on current biologic therapy. In: American College of Rheumatology. (American College of Rheumatology, Boston, 2014)
102. Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997;176(3):578–585.
103. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347(1):26–34.
104. Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208(9):1375–1385.
105. Haumont M, Jacquet A, Massaer M, et al. Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells. Virus Res. 1996;40(2):199–204.
106. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503.
107. Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193(4):1920–1930.
108. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096.
109. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–1032.
110. Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279–1287.
111. Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124(19):2921–2929.